Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Zhi-Hong Liu, M.D., Nanjing University School of Medicine
ClinicalTrials.gov Identifier:
NCT00801268
First received: November 25, 2008
Last updated: August 30, 2013
Last verified: March 2013

November 25, 2008
August 30, 2013
November 2008
November 2013   (final data collection date for primary outcome measure)
MRI calculated kidney volume, eGFR [ Time Frame: Every 3-6months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00801268 on ClinicalTrials.gov Archive Site
End-stage kidney disease (ESRD) [ Time Frame: every 2months ] [ Designated as safety issue: Yes ]
ESRD [ Time Frame: every 2months ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease
Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Triptolide has been approve effective in animal model.

Randomized

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Polycystic Kidney
  • Drug: tripterygium wilfordii
    TW,60mg/d
  • Drug: Emodin
    100mg/d
    Other Name: Frangula emodin,Frangulic acid
  • Active Comparator: emodin
    Intervention: Drug: Emodin
  • Experimental: Triptolide Woldifii
    TW60mg/d
    Intervention: Drug: tripterygium wilfordii
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
300
November 2013
November 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinically established ADPKD
  • eGFR>30ml/min.
  • Chinese nationality

Exclusion Criteria:

  • Uncontrolled infections
  • Non-ADPKD complications
Both
15 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00801268
NJCT-0802
Yes
Zhi-Hong Liu, M.D., Nanjing University School of Medicine
Zhi-Hong Liu, M.D.
Not Provided
Principal Investigator: Liu Zhihong, Master Research Institute of Nephrology, Jinling Hospital
Nanjing University School of Medicine
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP